Scientists have found the mechanism by which a new mutation in the surfactant protein A1 (SFTPA1) gene leads to…
Articles by Joana Carvalho, PhD
Ofev (nintedanib) reduced lung function decline by more than 50% in patients with progressive fibrosing interstitial lung diseases (ILDs),…
Blocking the activity of interleukin-11 (IL-11) — a molecule that mediates immune and inflammatory responses — reverses tissue scarring,…
A small RNA molecule called miR-133a can prevent tissue scarring (fibrosis) in people with idiopathic pulmonary fibrosis (IPF)…
Weight loss is more common among patients with idiopathic pulmonary fibrosis (IPF) who are being treated with Ofev (nintedanib),…
Nitric oxide, a gas that induces the relaxation and widening of lung airways, has received orphan drug designation…
N115, EmphyCorp‘s investigational non-steroidal nasal spray for the treatment of interstitial lung diseases (ILDs), has completed a…
NP-120 (ifenprodil), an oral small molecule being repurposed by Algernon Pharmaceuticals for the treatment of idiopathic pulmonary fibrosis…
Lack of tissue oxygenation, also known as hypoxia, is involved in the development and progression of idiopathic pulmonary fibrosis…
NP-120, Algernon Pharmaceuticals‘ repurposed lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF), surpassed two other globally…